EA201391228A1 - (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR - Google Patents
(ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChRInfo
- Publication number
- EA201391228A1 EA201391228A1 EA201391228A EA201391228A EA201391228A1 EA 201391228 A1 EA201391228 A1 EA 201391228A1 EA 201391228 A EA201391228 A EA 201391228A EA 201391228 A EA201391228 A EA 201391228A EA 201391228 A1 EA201391228 A1 EA 201391228A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyridin
- modulators
- alsteric
- benzylamides
- nachr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Настоящее изобретение относится к (пиридин-4-ил) бензиламидным производным и их фармацевтически приемлемым солям, способам их получения, фармацевтическим композициям, содержащим их, и к их применению в терапии. Настоящее изобретение, в частности, относится к позитивным аллостерическим модуляторам никотиновых ацетилхолиновых рецепторов, причем такие позитивные аллостерические модуляторы обладают способностью повышать эффективность агонистов никотиновых рецепторов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11155937 | 2011-02-25 | ||
PCT/EP2012/053047 WO2012113850A2 (en) | 2011-02-25 | 2012-02-23 | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201391228A1 true EA201391228A1 (ru) | 2013-12-30 |
EA022164B1 EA022164B1 (ru) | 2015-11-30 |
Family
ID=44259750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391228A EA022164B1 (ru) | 2011-02-25 | 2012-02-23 | (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP2678315B1 (ru) |
JP (1) | JP5841617B2 (ru) |
KR (1) | KR101851140B1 (ru) |
CN (1) | CN103402983B (ru) |
AU (1) | AU2012219537B2 (ru) |
BR (1) | BR112013021599A2 (ru) |
CA (1) | CA2824350C (ru) |
CL (1) | CL2013002424A1 (ru) |
EA (1) | EA022164B1 (ru) |
ES (1) | ES2563113T3 (ru) |
HK (1) | HK1189222A1 (ru) |
IL (1) | IL228054A (ru) |
MX (1) | MX345656B (ru) |
MY (1) | MY161236A (ru) |
SG (1) | SG192939A1 (ru) |
UA (1) | UA109803C2 (ru) |
WO (1) | WO2012113850A2 (ru) |
ZA (1) | ZA201306385B (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
CA2697974C (en) | 2007-10-18 | 2015-06-30 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles |
KR101564303B1 (ko) | 2008-03-19 | 2015-11-06 | 얀센 파마슈티카 엔.브이. | 니코틴성 아세틸콜린 수용체 조절제로서의 삼치환된 1,2,4-트리아졸 |
WO2009135944A1 (en) | 2008-05-09 | 2009-11-12 | Janssen Pharmaceutica Nv | Trisubstituted pyrazoles as acetylcholine receptor modulators |
TW201722962A (zh) | 2015-08-19 | 2017-07-01 | 安斯泰來製藥股份有限公司 | 四氫氧呯並吡啶化合物 |
CA2998375A1 (en) | 2015-09-17 | 2017-03-23 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
CN108689957B (zh) * | 2018-07-23 | 2020-07-03 | 南京药石科技股份有限公司 | 一种2r/2s-三氟甲基吗啉及其盐酸盐的制备方法和应用 |
EP3856180A1 (en) * | 2018-09-24 | 2021-08-04 | Astrazeneca AB | Azd0328 dosage regime for treating cognitive impairment |
CN113264867A (zh) * | 2021-06-08 | 2021-08-17 | 安徽星宇化工有限公司 | 一种顺式2,6-二甲基哌啶的制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1913901A (zh) * | 2004-02-04 | 2007-02-14 | 神经研究公司 | 作为胆碱能受体调节剂的二氮杂双环芳基衍生物 |
EP1845081A4 (en) * | 2005-02-01 | 2009-03-25 | Takeda Pharmaceutical | amide |
US20080261999A1 (en) * | 2005-03-04 | 2008-10-23 | Fionna Mitchell Martin | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists |
EA015034B1 (ru) | 2005-09-13 | 2011-04-29 | Янссен Фармацевтика Н.В. | 2-анилин-4-арилзамещенные тиазольные производные |
JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
EP2018380B1 (en) * | 2006-05-19 | 2011-10-19 | Abbott Laboratories | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
JP5564251B2 (ja) * | 2006-06-29 | 2014-07-30 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するためのビアリール組成物および方法 |
ZA200901521B (en) * | 2006-10-25 | 2010-06-30 | Neurosearch As | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
CA2697974C (en) | 2007-10-18 | 2015-06-30 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles |
JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
KR101564303B1 (ko) | 2008-03-19 | 2015-11-06 | 얀센 파마슈티카 엔.브이. | 니코틴성 아세틸콜린 수용체 조절제로서의 삼치환된 1,2,4-트리아졸 |
US20110112103A1 (en) * | 2008-04-22 | 2011-05-12 | Daiichi Sankyo Company, Limited | 5-hydroxypyrimidine-4-carboxamide compound |
WO2009135944A1 (en) | 2008-05-09 | 2009-11-12 | Janssen Pharmaceutica Nv | Trisubstituted pyrazoles as acetylcholine receptor modulators |
-
2012
- 2012-02-23 CA CA2824350A patent/CA2824350C/en active Active
- 2012-02-23 UA UAA201308962A patent/UA109803C2/ru unknown
- 2012-02-23 CN CN201280010276.7A patent/CN103402983B/zh not_active Expired - Fee Related
- 2012-02-23 AU AU2012219537A patent/AU2012219537B2/en not_active Ceased
- 2012-02-23 EA EA201391228A patent/EA022164B1/ru not_active IP Right Cessation
- 2012-02-23 MY MYPI2013003103A patent/MY161236A/en unknown
- 2012-02-23 BR BR112013021599A patent/BR112013021599A2/pt not_active Application Discontinuation
- 2012-02-23 SG SG2013064225A patent/SG192939A1/en unknown
- 2012-02-23 JP JP2013554890A patent/JP5841617B2/ja not_active Expired - Fee Related
- 2012-02-23 ES ES12704845.2T patent/ES2563113T3/es active Active
- 2012-02-23 EP EP12704845.2A patent/EP2678315B1/en not_active Not-in-force
- 2012-02-23 KR KR1020137023963A patent/KR101851140B1/ko active IP Right Grant
- 2012-02-23 WO PCT/EP2012/053047 patent/WO2012113850A2/en active Application Filing
- 2012-02-23 MX MX2013009798A patent/MX345656B/es active IP Right Grant
-
2013
- 2013-08-21 IL IL228054A patent/IL228054A/en active IP Right Grant
- 2013-08-22 CL CL2013002424A patent/CL2013002424A1/es unknown
- 2013-08-23 ZA ZA2013/06385A patent/ZA201306385B/en unknown
-
2014
- 2014-03-04 HK HK14102158.8A patent/HK1189222A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA201306385B (en) | 2015-03-25 |
JP2014506587A (ja) | 2014-03-17 |
AU2012219537B2 (en) | 2016-07-28 |
KR20140014163A (ko) | 2014-02-05 |
SG192939A1 (en) | 2013-09-30 |
CN103402983B (zh) | 2015-12-23 |
MX345656B (es) | 2017-02-08 |
MY161236A (en) | 2017-04-14 |
WO2012113850A3 (en) | 2012-10-18 |
AU2012219537A1 (en) | 2013-07-18 |
JP5841617B2 (ja) | 2016-01-13 |
IL228054A (en) | 2016-06-30 |
KR101851140B1 (ko) | 2018-04-23 |
HK1189222A1 (zh) | 2014-05-30 |
EA022164B1 (ru) | 2015-11-30 |
MX2013009798A (es) | 2013-09-26 |
ES2563113T3 (es) | 2016-03-10 |
NZ612688A (en) | 2015-08-28 |
EP2678315B1 (en) | 2015-12-16 |
IL228054A0 (en) | 2013-09-30 |
EP2678315A2 (en) | 2014-01-01 |
CN103402983A (zh) | 2013-11-20 |
CA2824350A1 (en) | 2012-08-30 |
WO2012113850A2 (en) | 2012-08-30 |
CA2824350C (en) | 2019-07-02 |
BR112013021599A2 (pt) | 2016-11-16 |
CL2013002424A1 (es) | 2014-03-28 |
UA109803C2 (xx) | 2015-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201290394A1 (ru) | Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7 | |
EA201391228A1 (ru) | (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR | |
EA201071288A1 (ru) | Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина | |
EA201401351A1 (ru) | Производные бензимидазол-пролина | |
EA201201680A1 (ru) | Морфолинопиримидины и их применение в терапии | |
EA201391285A1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201270428A1 (ru) | Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины | |
UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
EA201100030A1 (ru) | Пиразольные соединения 436 | |
EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
EA201591195A1 (ru) | Новые хинолоновые производные | |
EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
EA201190142A1 (ru) | Производные пиразола, используемые в качестве антагонистов рецептора ccr4 | |
EA201270741A1 (ru) | Пероральные композиции и липофильные соли метилналтрексона | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
EA201600394A1 (ru) | Трициклические соединения пиперидина | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
EA201391710A1 (ru) | Замещенные производные индола для лечения иммунологических расстройств | |
UA110822C2 (uk) | Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів | |
MY166463A (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
EA201600166A1 (ru) | Производные пиперидина и азепина как модуляторы рецептора прокинетицина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |